However, despite the presence of the neutralizing antibodies in sensitized mice, intranasal IL13-PE therapy worked effectively as a therapeutic in the bleomycin-induced pulmonary fibrosis model. The gene discussed is IL13; the disease is pulmonary fibrosis.